<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CYTARABINE</span><br/>(sye-tare'a-been)<br/><span class="topboxtradename">ARA-C, </span><span class="topboxtradename">Cytosar-U, </span><span class="topboxtradename">Cytosine Arabinoside, </span><span class="topboxtradename">DepoCyt, </span><span class="topboxtradename">Tarabine<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antimetabolite, purine antagonist</span>; <span class="classification">immunosuppressant</span><br/><b>Prototype: </b>6-mercaptopurine<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL liposomal, 20 mg/mL, 100 mg, 500 mg, 1g, 2 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Pyrimidine analog with cell phase specificity affecting rapidly dividing cells in S phase (DNA synthesis). In certain conditions
         prevents development of cell from G<sub>1</sub> to S phase. Interferes with DNA and RNA synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antineoplastic agent which has strong myelosuppressant activity. Immunosuppressant properties are exhibited by obliterated
         cell-mediated immune responses, such as delayed hypersensitivity skin reactions.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To induce and maintain remission in acute myelocytic leukemia, acute lymphocytic leukemia, and meningeal leukemia and for
         treatment of lymphomas. Used in combination with other antineoplastics in established chemotherapeutic protocols.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of drug-induced myelosuppression; immunization procedures; pregnancy (category D) particularly during first trimester,
         lactation. Safe use in infants not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired renal or hepatic function, gout, drug-induced myelosuppression.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Leukemias</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 200 mg/m<sup>2</sup> by continuous infusion over 24 h <span class="rdroute">SC</span> 1 mg/kg 12 times/wk <span class="rdroute">Intrathecal</span> 575 mg once q4d or once/d for 4 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intrathecal</span><br/><ul>
<li>For intrathecal injection, reconstitute with an isotonic, buffered diluent without preservatives. Follow manufacturer's recommendations.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct:</span>  Reconstitute with bacteriostatic water for injection (without benzyl alcohol for neonates) as follows: add 5 mL to the 100-mg
                  vial to yield 20 mg/mL; add 10 mL to the 500 mg vial to yield 50 mg/mL.   <span class="methodtype">IV Infusion:</span>  May be further diluted with 100 mL or more of D5W or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 100 mg or a fraction thereof over 3 min.  <span class="methodtype">IV Infusion:</span> Give over 30 min or longer depending on the total volume of IV solution to be infused.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Fluorouracil,</b>
<b>gentamicin,</b>
<b>heparin,</b>
<b>insulin,</b>
<b>nafcillin,</b>
<b>oxacillin,</b>
<b>penicillin G.</b>
<span class="incompattype">Y-site:</span>
<b>Allopurinol,</b>
<b>ganciclovir,</b>
<b>TPN.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store cytarabine in refrigerator until reconstituted. Reconstituted solutions may be stored at 15°30° C (59°86°
            F) for 48 h. Discard solutions with a slight haze.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Weight loss, sore throat, fever, thrombophlebitis and pain at injection site; pericarditis, bleeding (any site), pneumonia.
      Potentially carcinogenic and mutagenic. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> diarrhea, stomatitis, oral or anal inflammation or ulceration, esophagitis, anorexia, <span class="speceff-life">hemorrhage</span>, hepatotoxicity, jaundice. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Leukopenia, thrombocytopenia,</span> anemia, megaloblastosis, myelosuppression (reversible); transient hyperuricemia. <span class="typehead">CNS:</span> Headache, <span class="speceff-life">neurotoxicity</span>; peripheral neuropathy, brachial plexus neuropathy, personality change, neuritis, vertigo, lethargy, somnolence, confusion. <span class="typehead">Skin:</span> Rash, erythema, freckling, cellulitis, skin ulcerations, pruritus, urticaria, bulla formation, desquamation. <span class="typehead">Special Senses:</span> Conjunctivitis, keratitis, photophobia. <span class="typehead">Urogenital:</span> Renal dysfunction, urinary retention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> GI toxicity may decrease <b>digoxin</b> absorption; decreases <span class="classification">aminoglycosides</span> activity against <i>Klebsiella pneumoniae</i>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 2060 min SC. <span class="typehead">Distribution:</span> Crosses blood-brain barrier in moderate amounts; crosses placenta. <span class="typehead"> Metabolism:</span> Metabolized primarily in liver.  <span class="typehead">Elimination:</span> 80% excreted in urine in 24 h. <span class="typehead">Half-Life:</span> 13 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Inspect patient's mouth before the administration of each dose. Toxicity necessitating dosage alterations almost always occurs.
            Report adverse reactions immediately.
         </li>
<li>Lab tests: Hct and platelet counts and total and differential leukocyte counts should be evaluated daily during initial therapy.
            Serum uric acid and hepatic function tests should be performed at regular intervals throughout treatment period.
         </li>
<li>Hyperuricemia due to rapid destruction of neoplastic cells may accompany cytarabine therapy. A regimen that includes a uricosuric
            agent such as allopurinol, urine alkalinization, and adequate hydration may be started. To reduce potential for urate stone
            formation, fluids are forced in excess of 2 L, if tolerated. Consult physician.
         </li>
<li>Monitor I&amp;O ratio and pattern.</li>
<li>Monitor body temperature. Be alert to the most subtle signs of infection, especially low-grade fever, and report promptly.</li>
<li>When platelet count falls below 50,000/mm<sup>3</sup> and polymorphonuclear leukocytes to below 1000/mm<sup>3</sup>, therapy may be suspended. WBC nadir is usually reached in 57 d after therapy has been stopped. Therapy is restarted
            with appearance of bone marrow recovery and when preceding cell counts are reached.
         </li>
<li>Provide good oral hygiene to diminish adverse effects and chance of superinfection. Stomatitis and cheilosis usually appear
            510 d into the therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly protracted vomiting or signs of nephrotoxicity (see Appendix F).</li>
<li>Flu-like syndrome occurs usually within 612 wk after drug administration and may recur with successive therapy. Report
            chills, fever, achy joints and muscles.
         </li>
<li>Report any S&amp;S of superinfection (see Appendix F).</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>